The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 1 of the 22 sources its claims cite were checked for support.
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Open accessAbstract
PURPOSE: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NSCLC). METHODS: Patients received Dato-DXd 6 mg/kg or docetaxel 75 mg/m 2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Objective response rate, duration of response, and safety were secondary end points. RESULTS: In total, 299 and 305 patients were randomly assigned to receive Dato-DXd or docetaxel, respectively. The median PFS was 4.4 months (95% CI, 4.2 to 5.6) with Dato-DXd and 3.7 months (95% CI, 2.9 to 4.2) with docetaxel (hazard ratio [HR], 0.75 [95% CI, 0.62 to 0.91]; P = .004). The median OS was 12.9 months (95% CI, 11.0 to 13.9) and 11.8 months (95% CI, 10.1 to 12.8), respectively (HR, 0.94 [95% CI, 0.78 to 1.14]; P = .530). In the prespecified nonsquamous histology subgroup, the median PFS was 5.5 versus 3.6 months (HR, 0.63 [95% CI, 0.51 to 0.79]) and the median OS was 14.6 versus 12.3 months (HR, 0.84 [95% CI, 0.68 to 1.05]). In the squamous histology subgroup, the median PFS was 2.8 versus 3.9 months (HR, 1.41 [95% CI, 0.95 to 2.08]) and the median OS was 7.6 versus 9.4 months (HR, 1.32 [95% CI, 0.91 to 1.92]). Grade ≥3 treatment-related adverse events occurred in 25.6% and 42.1% of patients, and any-grade adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8.8% and 4.1% of patients, in the Dato-DXd and docetaxel groups, respectively. CONCLUSION: Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.
Overview
CoChat Summary
TL;DR
In this randomized phase III trial of previously treated advanced/metastatic NSCLC, datopotamab deruxtecan (Dato-DXd) improved progression-free survival and response outcomes versus docetaxel, but did not significantly improve overall survival. Benefit was driven by patients with nonsquamous histology, while squamous histology showed no PFS advantage and possible inferiority.
Key findings
- In the full analysis set, median PFS was 4.4 months with Dato-DXd vs 3.7 months with docetaxel (HR 0.75; 95% CI, 0.62 to 0.91; P = .004).
- In patients with nonsquamous tumors, median PFS was 5.5 vs 3.6 months (HR 0.63; 95% CI, 0.51 to 0.79), and median OS was 14.6 vs 12.3 months (HR 0.84; 95% CI, 0.68 to 1.05).
- In patients with squamous tumors, median PFS was 2.8 vs 3.9 months (HR 1.41; 95% CI, 0.95 to 2.08) and median OS was 7.6 vs 9.4 months (HR 1.32; 95% CI, 0.91 to 1.92).
- Confirmed ORR was 26.4% with Dato-DXd vs 12.8% with docetaxel; median DOR was 7.1 vs 5.6 months.
- Safety favored Dato-DXd for several high-grade outcomes: grade ≥3 TRAEs were 25.6% vs 42.1%, and treatment discontinuations were 8.1% vs 12.1%; however, adjudicated drug-related ILD occurred in 8.8% vs 4.1%, and 7 patients (2.4%) receiving Dato-DXd died from adjudicated drug-related ILD.
Methods
- Randomized, open-label, global phase III trial (TROPION-Lung01) comparing Dato-DXd 6 mg/kg vs docetaxel 75 mg/m² IV every 3 weeks; crossover was not permitted.
- Eligible patients had stage IIIB/C or IV NSCLC after prior therapy; the trial enrolled 299 patients to Dato-DXd and 305 to docetaxel.
- Dual primary endpoints were PFS by blinded independent central review (RECIST 1.1) and OS; analyses used Kaplan-Meier estimates and stratified Cox regression, with safety assessed in treated patients.
Limitations
- The paper states the open-label study design is a limitation.
- The trial was not powered to demonstrate statistical significance within histologic subgroups; this is stated in the discussion and is evident from subgroup interpretation.
- A slight imbalance in pretreatment dropout rates was observed (1% in Dato-DXd vs 5% in docetaxel), though the authors say it was unlikely to affect outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
1 Valid · 0 Not valid · 12 Not checked · 56 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No late-onset toxicities were observed for Dato-DXd in this study.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with a confirmed objective response by blinded independent central review was 26.4% (95% CI, 21.5 to 31.8) with Dato-DXd and 12.8% (95% CI, 9.3 to 17.1) with docetaxel (Table 2 ).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with nonsquamous tumors, the median OS was 14.6 months (95% CI, 12.4 to 16.0) with Dato-DXd and 12.3 months (95% CI, 10.7 to 14.0) with docetaxel (HR, 0.84 [95% CI, 0.68 to 1.05]; Fig 3 C).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interaction testing between treatment and histology also supported the OS histologic findings (Cox regression interaction, P = .0312; Data Supplement, Table S8).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In patients with squamous tumors, the median OS was 7.6 months (95% CI, 5.0 to 11.0) and 9.4 months (95% CI, 7.2 to 12.5) with Dato-DXd and docetaxel, respectively (HR, 1.32 [95% CI, 0.91 to 1.92]; Fig 3 D).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
30 more claims
Create a free account to see all 69 claims and to verify the 21 references still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from the Phase III TROPION-Breast01 and TROPION-Lung01trials demonstrated greater progression-free survival on Dato-DXd compared to standard-of-care therapy, leading to the FDA approval of Dato-DXd in metastatic HR + /HER2– breast cancer and EGFR + NSCLC135,136.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ocular surface and pulmonary toxicities are also commonly associated with trophoblast cell surface antigen 2 directed antibody-drug conjugates. 11 13 29”
From Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, randomised phase 3 trials of sacituzumab govitecan and datopotamab deruxtecan in biomarker unselected patients with previously treated, advanced NSCLC (regardless of actionable genomic alterations) did not reach statistical significance for overall survival improvement.”
In the citing paper
“In the large phase 3 TROPION-Lung01 trial, another trophoblast cell surface antigen 2 directed antibody-drug conjugate, datopotamab deruxtecan, showed an objective response rate of 26%, with a median progression-free survival of 4.4 months and an overall survival of 12.9 months, with no statistically significant difference in overall survival compared with docetaxel. 13”
Citations
Cites
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Self-citationShepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,181
Self-citationFossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309 · cited 1×
“%) receiving docetaxel; most events with Dato-DXd were grade 1 (82 [27.6”
InfluentialSelf-citationTrastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021 · cited 1×
“ILD is a known risk for deruxtecan-containing antibody – drug conjugates, 32 and management guidelines are in place.”
Self-citationReck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Self-citationHendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Self-citationGlobal variations in lung cancer incidence by histological subtype in 2020: a population-based study
Zhang, Y., Vaccarella, S., Morgan, E., Li, M., Etxeberria, J., Chokunonga, E., Manraj, S. S., Kamate, B., Omonisi, A., & Bray, F. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00444-8 · Cited by 445
Self-citationOkajima, D., Yasuda, S., Maejima, T., Karibe, T., Sakurai, K., Aida, T., Toki, T., Yamaguchi, J., Kitamura, M., Kamei, R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0206 · Cited by 339
Scagliotti, G., Brodowicz, T., Shepherd, F. A., Zielinski, C., Vansteenkiste, J., Manegold, C., Simms, L., Fossella, F., Sugarman, K., & Belani, C. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f7c6d4 · Cited by 252
Research works printed but not linked: 1
- Leighl N, Paz-Ares L, Rodriguez Abreu D, et al: 65O Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. IOTECH 20:100535, 2023
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Crescioli, S., Kaplon, H., Wang, L., Visweswaraiah, J., Kapoor, V., & Reichert, J. M. (2025) · mAbs · doi:10.1080/19420862.2024.2443538 · Cited by 171
Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01349 · Cited by 130
Self-citationCracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 114
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
Fang, W., Wu, L., Meng, X., Yao, Y., Zuo, W., Yao, W., Xie, Y., Zhang, Y., Cui, J., Zhang, Y., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2512071 · Cited by 107
Self-citation
Metadata
- Authors
- Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Hong, M. H., Felip, E., Hall, R., Juan-Vidal, O., Brungs, D., Lu, S., Garassino, M., Chargualaf, M., Zhang, Y., Howarth, P., Uema, D., Lisberg, A., Sands, J., for the TROPION-Lung01 Trial Investigators, Martinengo, G. L., Puig, J., Brungs, D., Gao, B., Nagria, A., Karapetis, C., Parakh, S., Park, J., Catala, G., Forget, F., Ocak, S., Basappa, N., Liu, G., Menjak, I., Shieh, B., Lu, S., Luo, F., Sun, H., Wang, J., Yao, Y., Zemanova, M., Bennouna, J., Girard, N., Greillier, L., Lamour, C., Lena, H., Mascaux, C., Mazieres, J., Moro-Sibilot, D., Pérol, M., Pons-Tostivint, E., Westeel, V., Atmaca, A., Greil, C., Reinmuth, N., Schumann, C., Wehler, T., Wolf, J., Ho, J., Bocskei, C., Cappuzzo, F., de Marinis, F., Proto, C., Mencoboni, M., Novello, S., Salvagni, S., Parra, H. S., Daga, H., Goto, Y., Hayashi, H., Kitazono, S., Yoh, K., Ko, R., Kondo, M., Kozuki, T., Kurata, T., Mizutani, H., Ohashi, K., Oizumi, S., Okamoto, I., Sakaguchi, S., Ozasa, H., Sugawara, S., Tambo, Y., Tamiya, M., Tanaka, H., Okamoto, I., Lopez-Lopez, F., Ramirez Godinez, F. J., Rodriguez Cid, J. R., Cornelissen, R., Gans, S., Stigt, J., Kowalski, D., Lowczak, A., Milanowski, J., Mróz, R., Ramlau, R., Acosta-Rivera, M., Ahn, M.-J., Chae, Y. S., Hong, M. H., Kang, J.-H., Kim, S.-W., Kim, J.-S., Kim, S. H., Lee, K. H., Lee, Y. G., Shim, B. Y., Ledin, E., Poddubskaya, E., Daniel Chan, B. Y., Jain, A., Tan, C. S., Areses, M. C., Cobo, M., Domine, M., Felip, E., Pradera, J. F., Isla, D., Vidal, O. J., Majem, M., Paz-Ares, L., Provencio, M., Reguart, N., Baz, D. V., Cerciello, F., Früh, M., Chang, W.-C., Chang, G.-C., Huang, W.-T., Ling, C.-C., Wei, Y.-F., Yang, T.-Y., Ahmad, T., Gomes, F., Mansy, T., Bruno, D., Castine, M., Fang, B., Garassino, M., Hall, R., Halmos, B., Jahangir, K., Johnson, M., Johnson, T., Kalmadi, S., Lawler, W., Lisberg, A., Sadiq, A., Sands, J., Solomon, B., & Veatch, A.
- Affiliations
- Kyushu University Hospital (JP)
- Hospital Universitario Virgen Macarena, Seville, Spain
- Hospital Universitari i Politecnic La Fe, Valencia, Spain
- Daiichi Sankyo (United States) (US)
- ORCID
- Tanaka, Kentaro
- Juan-Vidal, Oscar
- Chargualaf, Michael
- Zhang, Yong
- Howarth, Paul
- Uema, Deise
- Gao, Bo
- Parakh, Sagun
- Park, John
- Ocak, Sebahat
- Basappa, Naveen
- Liu, Geoffrey
- Menjak, Ines
- Luo, Feng
- Sun, Hongmei
- Wang, Jialei
- Yao, Yu
- Bennouna, Jaafar
- Greillier, Laurent
- Westeel, Virginie
- Greil, Christine
- Reinmuth, Niels
- Schumann, Christian
- Wehler, Thomas
- Wolf, Juergen
- Cappuzzo, Federico
- Proto, Claudia
- Novello, Silvia
- Daga, Haruko
- Goto, Yasushi
- Yoh, Kiyotaka
- Ko, Ryo
- Kondo, Masashi
- Kozuki, Toshiyuki
- Kurata, Takayasu
- Ohashi, Kadoaki
- Oizumi, Satoshi
- Sakaguchi, Satoshi
- Tambo, Yuichi
- Tamiya, Motohiro
- Tanaka, Hiroshi
- Kowalski, Dariusz
- Milanowski, Janusz
- Mróz, Robert
- Ramlau, Rodryg
- Chae, Yee Soo
- Kim, Sang-We
- Kim, Jin-Soo
- Kim, Se Hyun
- Lee, Ki Hyeong
- Shim, Byoung Yong
- Ledin, Evgeniy
- Jain, Amit
- Tan, Chee Seng
- Isla, Dolores
- Majem, Margarita
- Provencio, Mariano
- Cerciello, Ferdinando
- Wei, Yu-Feng
- Yang, Tsung-Ying
- Mansy, Talal
- Fang, Bruno
- Johnson, Melissa
- Lawler, William
- Solomon, Benjamin
- Venue
- Journal of Clinical Oncology
- Published
- 2025-01-20
- Volume
- 43
- Issue
- 3
- Pages
- 260-272
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC11771353
- OpenAlex
- W4402350756
- Semantic Scholar
- 3809d9a1f0a7e3848e76ff9c911340afab526bea
- Cited by
- 244
- References
- 32
- Citations by year
- 2026: 138 · 2025: 97
- FWCI
- 70.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
- Open Access CRIS of the University of Bern
- Funders
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- datopotamab deruxtecan, docetaxel, non-small cell lung cancer, metastatic lung cancer, previously treated patients, progression-free survival, overall survival, antibody-drug conjugates, lung squamous cell carcinoma, treatment safety, objective response rate, duration of response
- MeSH terms
- Docetaxel, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Immunoconjugates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. https://app.cochat.ai/papers/10.1200/jco-24-01544
- The paper
- Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Hong, M. H., Felip, E., Hall, R., Juan-Vidal, O., Brungs, D., . . . Veatch, A. (2025). Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01544
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.